Jennifer Goss
Family · Grenada, MSNPI 1548608128
Payments from drug & device makers
Across 304 payments — averaging $13.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$821
- AstraZeneca$562
- GSK$525
- Novo Nordisk$398
- Bayer$329
- Lilly USA, LLC$260
- plus $1K from 27 others
What the payments were for
- Food & beverage$4,206100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $821 |
| AstraZeneca | 33 | $562 |
| GSK | 45 | $525 |
| Novo Nordisk | 33 | $398 |
| Bayer | 20 | $329 |
| Lilly USA, LLC | 16 | $260 |
| Novartis | 12 | $196 |
| Amgen | 8 | $129 |
| Ironwood Pharmaceuticals, Inc | 8 | $126 |
| Biohaven Pharmaceuticals, Inc. | 6 | $123 |
| Pfizer | 5 | $85 |
| Esperion Therapeutics, Inc. | 5 | $74 |
| Astellas Pharma US Inc | 3 | $53 |
| Mylan Specialty L.p. | 2 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Abbott | 2 | $42 |
| Corcept Therapeutics | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Gilead | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Genentech USA, Inc. | 2 | $25 |
| Boehringer Ingelheim | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $17 |
| Ardelyx, Inc. | 1 | $17 |
| Vertex | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $12 |
| Boston Scientific | 1 | $12 |
| Redhill Biopharma Inc. | 1 | $12 |
How this compares
$4,206 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 173 | $217,922 |
| MounjaroTirzepatide | 140 | $170,872 |
| TradjentaLinagliptin | 82 | $79,412 |
| FarxigaDapagliflozin Propanediol | 64 | $79,240 |
| LinzessLinaclotide | 71 | $78,988 |
| JardianceEmpagliflozin | 52 | $54,326 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $47,017 |
| KerendiaFinerenone | 42 | $41,293 |
| EliquisApixaban | 42 | $40,287 |
| EntrestoSacubitril/Valsartan | 35 | $38,476 |
| TrulicityDulaglutide | 34 | $35,664 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $25,908 |
| Tresiba Flextouch U-100Insulin Degludec | 51 | $24,412 |
| Repatha SureclickEvolocumab | 23 | $23,648 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $21,705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $398 | $239,173185 claims |
| Lilly USA, LLCMounjaro, Trulicity | $260 | $206,536174 claims |
| Boehringer IngelheimTradjenta, Jardiance, Glyxambi, Trijardy Xr | $25 | $164,040168 claims |
| AbbVieLinzess, Synthroid | $821 | $82,07895 claims |
| AstraZenecaFarxiga, Symbicort | $562 | $81,70375 claims |
| BayerKerendia | $329 | $41,29342 claims |
| PfizerEliquis | $85 | $40,28742 claims |
| NovartisEntresto | $196 | $38,47635 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $525 | $27,75742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.
Other family in Grenada
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.